1. United Ststes Food and Drug Administration (USFDA). Press Announcements: FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder; 2009. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm177401.html. Accessed June 29 2020.

2. Patches

3. Citrome L, Walling D, Zeni C, Komaroff M, Park A Efficacy and safety of an asenapine transdermal system (HP-3070) for treatment of adults with schizophrenia: a Phase 3 randomized, placebo-controlled, inpatient study. Presented at: Psych Congress 2019; October 3-6, 2019; San Diego, CA. Poster 122.

4. Mohr P, Rietscher R, Eifler R, Bourquain O, inventors. LTS Lohmann Therapie-Systeme AG, Andernach, Germany, applicant. Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene. WO2018115010A1; 2018.

5. Mohr P, Rietscher R, Eifler R, Bourquain O, inventors. LTS Lohmann Therapie-Systeme AG, Andernach, Germany, applicant. Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer. WO2019002204A1; 2019.